The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma
S. Hansen (Copenhagen, Denmark), C. Ulrik (Hvidovre, Denmark), O. Hilberg (Vejle, Denmark), A. Von Bülow (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), C. Johnsen (Gentofte, Denmark), J. Schmid (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), K. Assing (Aalborg, Denmark), A. Wimmer-Aune (Aalborg, Denmark), N. Krogh (Copenhagen, Denmark), L. Rasmussen (Gentofte, Denmark), C. Porsbjerg (Copenhagen, Denmark)
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Hansen (Copenhagen, Denmark), C. Ulrik (Hvidovre, Denmark), O. Hilberg (Vejle, Denmark), A. Von Bülow (Copenhagen, Denmark), A. Christiansen (Odense, Denmark), C. Johnsen (Gentofte, Denmark), J. Schmid (Aarhus, Denmark), A. Bjerrum (Aarhus, Denmark), K. Assing (Aalborg, Denmark), A. Wimmer-Aune (Aalborg, Denmark), N. Krogh (Copenhagen, Denmark), L. Rasmussen (Gentofte, Denmark), C. Porsbjerg (Copenhagen, Denmark). The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma. 3742
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: